Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bifidobacterium longum capable of relieving atopic dermatitis and application thereof

A technology for atopic dermatitis and Bifidobacterium longum, applied in the fields of microbiology and medicine, can solve problems such as poor tolerance of patients, difficulty in AD treatment, adverse reactions, etc.

Active Publication Date: 2019-04-19
JIANGNAN UNIV
View PDF5 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, the above-mentioned drugs have relatively large adverse reactions, and most patients have concerns about hormone drugs, which not only bring great difficulties to the treatment of AD, but also bring great troubles to the lives of patients. In addition, these drugs are poorly tolerated by individual patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bifidobacterium longum capable of relieving atopic dermatitis and application thereof
  • Bifidobacterium longum capable of relieving atopic dermatitis and application thereof
  • Bifidobacterium longum capable of relieving atopic dermatitis and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0055] Embodiment 1: Screening and strain identification of Bifidobacterium longum

[0056] 1. Screening

[0057] Taking healthy human feces from Hangzhou, Zhejiang as the sample, the sample was pretreated and stored in a -80°C refrigerator in about 20% glycerin. After taking out and thawing, mix the sample and add 0.5mL sample to 4.5mL. 0.9% normal saline containing 0.05% cysteine ​​was used for gradient dilution, and the appropriate gradient dilution was selected and spread on the MRS solid medium added with 0.05% cysteine, cultured at 37°C for 48 hours, and typical colonies were picked Streak on MRS solid medium for purification, pick a single colony and transfer to MRS liquid medium (containing 0.05% cysteine) for enrichment, and preserve in 30% glycerol to obtain strain CCFM1029, strain A1 and strain A2.

[0058] 2. Identification

[0059] The genome of CCFM1029, A1, A2 was extracted, and the 16S rDNA of CCFM1029, A1, A2 was amplified and sequenced (by Yingwei Jieji (Sh...

Embodiment 2

[0060] Embodiment 2: the cultivation of Bifidobacterium longum

[0061] After inserting Bifidobacterium longum (Bifidobacterium longum) CCFM1029 into MRS solid medium (containing 0.05% cysteine) and culturing at 37°C for 48 hours, the colonies were observed, and the colonies were found to be convex to cushion-like, with complete, soft edges. Moist, white and glossy.

[0062] Insert Bifidobacterium longum CCFM1029 into MRS liquid medium (containing 0.05% cysteine) and culture it anaerobically at 37°C for 24 h, then transfer to fresh MRS liquid medium (containing 0.05% cysteine). acid), cultivated under the same conditions for 24 hours, centrifuged the cells at 6000 g for 15 min, washed the cells with 0.9% normal saline and centrifuged again at 6000 g for 10 min to obtain the cells, resuspended with 30% sucrose solution, and frozen at -80°C until use.

Embodiment 3

[0063] Example 3: Effects of different Bifidobacterium longum on ear thickness of mice with atopic dermatitis

[0064] Take 50 healthy female C57BL / 6 mice with a body weight of 18-20g, and divide them into 5 groups randomly, 10 mice in each group. The 5 groups are: blank group (Control), administration of 2,4-dinitrofluorobenzene (2,4-dinitrofluorobenzene, DNFB) model group (Model), the CCFM1029 group administered with Bifidobacterium longum CCFM1029, the A1 group administered with Bifidobacterium longum A1, the A2 group administered with Bifidobacterium longum A2, wherein , CCFM1029 group, A1 group, A2 group are treatment groups.

[0065] The experiment lasted for four weeks: the first week was the adaptation period of the mice; the second week began to gavage the mice until the end of the experiment. The total amount of live bacteria is 1×10 9 CFU) / head / time for intragastric administration, the blank group and the model group were not intervened with bacterial solution, an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to bifidobacterium longum capable of relieving atopic dermatitis and application thereof, and belongs to the technical field of microorganisms and the technical field of medicine. Bifidobacterium longum has the effect of relieving atopic dermatitis, and has the advantages that the ear swelling degree of a mouse with atopic dermatitis is remarkably decreased; dermal pathologysymptoms of the mouse with atopic dermatitis are relieved remarkably, and inflammatory cell infiltration is relieved; the serum IgE of the mouse with atopic dermatitis is reduced remarkably; the levelof IL-4 and IL-13 in skin tissue of the mouse with atopic dermatitis is decreased remarkably; the level of histamine in the skin tissue of the mouse with atopic dermatitis is decreased remarkably. Inthis way, bifidobacterium longum has broad application prospects in preparation of products for preventing and / or treating atopic dermatitis.

Description

technical field [0001] The invention relates to a strain of bifidobacterium longum capable of alleviating atopic dermatitis and its application, belonging to the technical field of microorganisms and the technical field of medicine. Background technique [0002] Atopic dermatitis (Atopic Dermatitis, AD) is a chronic, relapsing, inflammatory skin disease that is often accompanied by severe itching and other allergic diseases. Meanwhile, AD is a common non-communicable skin disease, affecting up to 20% of children and 2-8% of adults in most countries of the world (Wollenberg A et al., 2018), and its clinical manifestations are diverse, according to its Occurrence, development, and distribution characteristics can be divided into three stages: infancy, childhood, adolescence, and adulthood. Among them, most AD patients develop in infancy, and severe cases even last until adulthood. Due to its repeated severe Affecting the quality of life of patients is one of the world's publi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N1/20A23L33/135A61K35/745A61P17/00A61P29/00C12R1/01
CPCA61P17/00A61P29/00A23L33/135A23V2002/00A61K2035/115C12R2001/01C12N1/205A23V2400/533A23V2200/318C12N1/20A61K35/745C12N2500/34C12N2500/46C12N2500/74C12N2523/00
Inventor 陈卫陆文伟方志锋翟齐啸杨波赵建新张灏
Owner JIANGNAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com